Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Topiramate extended release - Upsher-Smith

Next Previous
Drug Profile

Topiramate extended release - Upsher-Smith

Alternative Names: Qudexy XR; USL-255

Latest Information Update: 20 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Upsher-Smith
  • Developer SK Chemicals; Upsher-Smith
  • Class Antiepileptic drugs; Antimigraines; Dioxolanes; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Pyrans; Small molecules; Sulfonic acids
  • Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Lennox-Gastaut syndrome; Migraine; Partial epilepsies; Tonic-clonic epilepsy

Most Recent Events

  • 28 Dec 2022 No development reported - Phase-I for Migraine (Prevention, In volunteers) in South Korea (PO)
  • 06 Oct 2020 SK Chemicals completes Phase-I clinical trials in Migraine (In volunteers, Prevention) in South Korea (PO) (NCT04401137)
  • 01 Jul 2020 Phase-I clinical trials in Migraine (In volunteers, Prevention) in South Korea (PO) (NCT04401137)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top